TW316904B - - Google Patents

Download PDF

Info

Publication number
TW316904B
TW316904B TW083105518A TW83105518A TW316904B TW 316904 B TW316904 B TW 316904B TW 083105518 A TW083105518 A TW 083105518A TW 83105518 A TW83105518 A TW 83105518A TW 316904 B TW316904 B TW 316904B
Authority
TW
Taiwan
Prior art keywords
ethyl
methoxyphenyl
pyrazolo
tetrahydro
cyclopentyl
Prior art date
Application number
TW083105518A
Other languages
English (en)
Chinese (zh)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of TW316904B publication Critical patent/TW316904B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW083105518A 1993-07-06 1994-06-17 TW316904B (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8829293A 1993-07-06 1993-07-06

Publications (1)

Publication Number Publication Date
TW316904B true TW316904B (cg-RX-API-DMAC10.html) 1997-10-01

Family

ID=22210524

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083105518A TW316904B (cg-RX-API-DMAC10.html) 1993-07-06 1994-06-17

Country Status (20)

Country Link
EP (1) EP0707585A1 (cg-RX-API-DMAC10.html)
JP (1) JP2944048B2 (cg-RX-API-DMAC10.html)
KR (1) KR100228949B1 (cg-RX-API-DMAC10.html)
CN (1) CN1048015C (cg-RX-API-DMAC10.html)
AU (1) AU695301B2 (cg-RX-API-DMAC10.html)
BR (1) BR9406946A (cg-RX-API-DMAC10.html)
CA (1) CA2166721C (cg-RX-API-DMAC10.html)
CZ (1) CZ3696A3 (cg-RX-API-DMAC10.html)
EG (1) EG20513A (cg-RX-API-DMAC10.html)
FI (1) FI943208L (cg-RX-API-DMAC10.html)
HU (1) HUT74170A (cg-RX-API-DMAC10.html)
IL (1) IL110175A (cg-RX-API-DMAC10.html)
MX (1) MX9405132A (cg-RX-API-DMAC10.html)
NO (1) NO305029B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ266525A (cg-RX-API-DMAC10.html)
PL (1) PL312426A1 (cg-RX-API-DMAC10.html)
RU (1) RU2131876C1 (cg-RX-API-DMAC10.html)
TW (1) TW316904B (cg-RX-API-DMAC10.html)
WO (1) WO1995001980A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA944844B (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ292991A (en) * 1994-10-20 1999-02-25 Pfizer Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
DE69525978T2 (de) * 1995-06-06 2002-12-19 Pfizer Trizyclische 5,6-dihydro-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-alpha)pyridine
AP932A (en) * 1996-08-26 2001-02-02 Pfizer Tricyclic 5,6-dihydro-9H-pyrazolo (3,4c)-1,2,4,-triazolo (4,3-a) pyridines.
JP3554337B2 (ja) * 1996-09-04 2004-08-18 ファイザー・インク インダゾール誘導体、およびホスホジエステラーゼ(pde)タイプ4と腫瘍壊死因子(tnf)産生の阻害剤としてのインダゾール誘導体の使用
IL158649A0 (en) * 1997-09-26 2004-05-12 Zentaris Gmbh Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
IL142959A0 (en) 1998-12-23 2002-04-21 Du Pont Pharm Co Nitrogen containing heterobicycles as factor xa inhibitors
US6326495B2 (en) 1999-04-30 2001-12-04 Pfizer Inc. Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
EP1671651B1 (en) 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
TWI243055B (en) * 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
BR0113176A (pt) * 2000-08-10 2003-06-17 Pharmacia Italia Spa Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
DE60118004T2 (de) * 2000-08-14 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Substituierte pyrazole
US6960595B2 (en) * 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
US6750225B2 (en) 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
CA2441772A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors
JP4196678B2 (ja) * 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
IL160693A0 (en) * 2001-09-21 2004-08-31 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7468376B2 (en) 2003-02-27 2008-12-23 Palau Pharma, S.A. Pyrazolopyridine derivates
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR050188A1 (es) * 2004-08-03 2006-10-04 Uriach Y Compania S A J Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
DE102005031580A1 (de) * 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
BR112016002789A2 (pt) 2013-08-09 2017-11-21 Ardelyx Inc compostos e métodos para inibir transporte de fosfato
CN110357888A (zh) * 2018-04-09 2019-10-22 南京药捷安康生物科技有限公司 杂环磷酸二酯酶抑制剂及其用途
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
FR1463883A (fr) * 1964-09-08 1966-07-22 Ciba Geigy Procédé de préparation de triaza-composés bicycliques
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
HU183325B (en) * 1981-02-11 1984-04-28 Richter Gedeon Vegyeszet Process for preparing new apovincaminol-3',4',5'-trimethoxy-benzoates substituted with a nitro group
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
FR2525602A1 (fr) * 1982-04-21 1983-10-28 Synthelabo Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines

Also Published As

Publication number Publication date
FI943208A7 (fi) 1995-01-07
MX9405132A (es) 1995-01-31
RU2131876C1 (ru) 1999-06-20
FI943208A0 (fi) 1994-07-05
HUT74170A (en) 1996-11-28
KR960703852A (ko) 1996-08-31
AU6805794A (en) 1995-02-06
CA2166721C (en) 1999-07-27
EP0707585A1 (en) 1996-04-24
WO1995001980A1 (en) 1995-01-19
NO960056L (no) 1996-01-05
NZ266525A (en) 1997-10-24
EG20513A (en) 1999-06-30
NO960056D0 (no) 1996-01-05
BR9406946A (pt) 1996-08-06
CA2166721A1 (en) 1995-01-19
CN1048015C (zh) 2000-01-05
CZ3696A3 (en) 1997-06-11
IL110175A0 (en) 1994-10-07
ZA944844B (en) 1996-01-05
FI943208L (fi) 1995-01-07
NO305029B1 (no) 1999-03-22
PL312426A1 (en) 1996-04-29
JPH08507084A (ja) 1996-07-30
HU9503934D0 (en) 1996-03-28
IL110175A (en) 2000-01-31
JP2944048B2 (ja) 1999-08-30
CN1129940A (zh) 1996-08-28
AU695301B2 (en) 1998-08-13
KR100228949B1 (ko) 1999-11-01

Similar Documents

Publication Publication Date Title
TW316904B (cg-RX-API-DMAC10.html)
US11884680B2 (en) Bromodomain inhibitors
JP6856614B2 (ja) 1,4−二置換ピリダジン誘導体およびsmn欠損に関連する状態を処置するためのその使用
JP2802547B2 (ja) 抗炎症剤としてのイソキサゾリン化合物
JP5624762B2 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
JP6289485B2 (ja) Pde4のヘテロアリール阻害剤
JP6256771B2 (ja) ヒストンデメチラーゼ阻害剤
TWI357327B (en) Pyrazoline compounds
AU684887B2 (en) Isoxazoline compounds as inhibitors of TNF release
WO2007055418A1 (ja) アザ置換スピロ誘導体
MX2014013549A (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
UA73492C2 (en) Aromatic heterocyclic compounds as antiinflammatory agents
WO2004024693A1 (ja) Hivインテグラーゼ阻害活性を有するヘテロ環化合物
WO2000066551A1 (en) Cyclic amide compounds, process for the preparation of the same and uses thereof
JPH09511758A (ja) 二環式テトラヒドロピラゾロピリジンおよび医薬としてのその使用
AU2003235259A1 (en) Benzimidazole derivatives
JP4166991B2 (ja) ピリドピリミジンまたはナフチリジン誘導体
TW460469B (en) Tricyclic 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridines
JP2021519316A (ja) Tlr2シグナル伝達の調節剤としての化合物
JP2018510131A (ja) Rorc2のスルホンアミド置換インドールモジュレーターおよびその使用方法
US10519138B2 (en) Modulators of SOCE, compositions, and uses thereof
JP4601038B2 (ja) インドリルマレイミド類
ITMI951687A1 (it) Composti indolici
ITMI950031A1 (it) Composti dibenzoalchilenici
ITMI950030A1 (it) Composti indolici